6584 A phase III study of CapeOx +/− lapatinib in HER2 positive locally-advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results
Hecht, J, Bang, Y, Sobrero, A, Elme, A, Patel, G, Park, J, Kemner, A, Afenjar, K, Koehler, M
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
242P Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
McAndrew, N.P., Chia, S., Puglisi, F., Bardia, A., Peron, Y. Izarzugaza, Schem, C., Xu, B., Le Du, F., Sharma, P., Afenjar, K., Akdere, M., Gonzalez, J.P. Zarate, Chattar, Y., Fasching, P.A.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)
Fasching, P.A., Slamon, D., Nowecki, Z., Kukielka-Budny, B.D., Stroyakovskiy, D., Yardley, D., Huang, C., Chan, A., Chia, S., Martin, M., Rugo, H.S., Loi, S., Hurvitz, S.A., Untch, M., Afenjar, K., Fresco, R., Danyliv, A., Ferrusi, I., Li, Z., Hortobagyi, G.N.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
168P - Results from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide
Chen, H.-W., Von Euw, E., Millan, P., Fresco, R., Carrez, S., Afenjar, K., Fung, H., Burton, M., Santiago, A., Guzman, R., Villalobos, I., Press, M., Eiermann, W., Slamon, D.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
168PResults from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide
Chen, H-W, Von Euw, E, Millan, P, Fresco, R, Carrez, S, Afenjar, K, Fung, H, Burton, M, Santiago, A, Guzman, R, Villalobos, I, Press, M, Eiermann, W, Slamon, D
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Results from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide
Chen, H.-W., Von Euw, E., Millan, P., Fresco, R., Carrez, S., Afenjar, K., Fung, H., Burton, M., Santiago, A., Guzman, R., Villalobos, I., Press, M., Eiermann, W., Slamon, D.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)
Barrios, C.H., Harbeck, N., Hortobagyi, G.N., O'Shaughnessy, J., Huang, C-S., Jimenez, M. Martin, Juric, D., Pistilli, B., Xu, B., De Laurentiis, M., Untch, M., Afenjar, K., Sum, E., Li, Z., Bolotova, N., Chiang, W., Rugo, H.S.
Published in ESMO open (01.05.2024)
Published in ESMO open (01.05.2024)
Get full text
Journal Article
Proton Pump Inhibitor (Ppis) Therapy May Impair Capecitabine (Cape) Efficacy in Metastatic Gastroesophageal Cancer (Gec), Results from the Trio-013/Logic Trial
Chu, M.P., Hecht, J.R., Slamon, D., Fontaine, A., King, K., Koski, S., Mulder, K., Hiller, J. Price, Scarfe, A., Spratlin, J., Bang, Y., Hoff, P.M., Sobrero, A., Qin, S., Afenjar, K., Houe, V., Huang, Y.J., Khan-Wasti, S., Chua, N., Sawyer, M.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
620PDPROTON PUMP INHIBITOR (PPIS) THERAPY MAY IMPAIR CAPECITABINE (CAPE) EFFICACY IN METASTATIC GASTROESOPHAGEAL CANCER (GEC), RESULTS FROM THE TRIO-013/LOGIC TRIAL
Chu, M.P., Hecht, J.R., Slamon, D., Fontaine, A., King, K., Koski, S., Mulder, K., Hiller, J. Price, Scarfe, A., Spratlin, J., Bang, Y., Hoff, P.M., Sobrero, A., Qin, S., Afenjar, K., Houe, V., Huang, Y.J., Khan-Wasti, S., Chua, N., Sawyer, M.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Results of a phase I / II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC)
Ramlau, R., Souquet, P.-J., Sun, X., Lopez-Vivanco, G., Afenjar, K., Colin, C., Krzakowski, M.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Results of a phase I / II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC)
Ramlau, R., Souquet, P.-J., Sun, X., Lopez-Vivanco, G., Afenjar, K., Colin, C., Krzakowski, M.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
P-566 Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Phase I and pharmacokinetic study
Robinet, G., Afenjar, K., Gouva, S., Planchard, D., Zorza, G., Tourani, J.
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2005)
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2005)
Get full text
Journal Article